Protective effect of dimethyl itaconate against fibroblast–myofibroblast differentiation during pulmonary fibrosis by inhibiting TXNIP

Author(s):  
Yong‐Yue Han ◽  
Xuan Gu ◽  
Chong‐Yang Yang ◽  
Hui‐Min Ji ◽  
Yue‐Jiao Lan ◽  
...  
Metabolites ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 258
Author(s):  
Hyo Yeong Lee ◽  
Somi Nam ◽  
Mi Jeong Kim ◽  
Su Jung Kim ◽  
Sung Hoon Back ◽  
...  

Idiopathic pulmonary fibrosis (IPF) is a serious lung disease characterized by excessive collagen matrix deposition and extracellular remodeling. Signaling pathways mediated by fibrotic cytokine transforming growth factor β1 (TGF-β1) make important contributions to pulmonary fibrosis, but it remains unclear how TGF-β1 alters metabolism and modulates the activation and differentiation of pulmonary fibroblasts. We found that TGF-β1 lowers NADH and NADH/NAD levels, possibly due to changes in the TCA cycle, resulting in reductions in the ATP level and oxidative phosphorylation in pulmonary fibroblasts. In addition, we showed that butyrate (C4), a short chain fatty acid (SCFA), exhibits potent antifibrotic activity by inhibiting expression of fibrosis markers. Butyrate treatment inhibited mitochondrial elongation in TGF-β1-treated lung fibroblasts and increased the mitochondrial membrane potential (MMP). Consistent with the mitochondrial observations, butyrate significantly increased ADP, ATP, NADH, and NADH/NAD levels in TGF-β1-treated pulmonary fibroblasts. Collectively, our findings indicate that TGF-β1 induces changes in mitochondrial dynamics and energy metabolism during myofibroblast differentiation, and that these changes can be modulated by butyrate, which enhances mitochondrial function.


2015 ◽  
Vol 12 (Supplement 1) ◽  
pp. S74-S75
Author(s):  
Shaik O. Rahaman ◽  
Lisa M. Grove ◽  
Brian D. Southern ◽  
Rachel G. Scheraga ◽  
Susamma Abraham ◽  
...  

2015 ◽  
Vol 11 (2) ◽  
pp. 247-255 ◽  
Author(s):  
Rong Yao ◽  
Yarong He ◽  
Zhi Zeng ◽  
Zongan Liang ◽  
Yu Cao

Sign in / Sign up

Export Citation Format

Share Document